 |
32 Diseases |  |
1 Trial |
|
1 Trial |  |
313 News |  |
| «123» |
- | anacetrapib (MK-0859) / Merck (MSD)
Journal: 2D QSAR studies on a series of (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-1,3-oxazolidin-2-one as CETP inhibitors. (Pubmed Central) - Sep 26, 2020
The best results were obtained with the SVR model. The results obtained may assist in the design of new CETP inhibitors.
- anacetrapib (MK-0859) / Merck (MSD)
[VIRTUAL] Biomarker-based Heart Failure Risk Stratification in Patients With Atherosclerotic Cardiovascular Disease: Observations From HPS-3/TIMI-55-REVEAL (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_54;
In patients with stable ASCVD, biomarkers of myocardial injury, hemodynamic stress, and inflammation provide incremental information for prediction of HHF. Future studies should address whether these patients are more likely to benefit from emerging HF preventive therapies.
- ||| atorvastatin / Generic mfg., anacetrapib (MK-0859) / Merck (MSD)
“Merck chose not to commercialize anacetrapib as the rate of CV events for the anacetrapib group was 10.8% vs. 11.8% on atorvastatin” Where’s Nissan when you need him: “Astounding. Blockbuster. Game-changing!” (Twitter) - Aug 27, 2020
- | anacetrapib (MK-0859) / Merck (MSD)
Journal: Effect of amorphous nanoparticle size on bioavailability of anacetrapib in dogs. (Pubmed Central) - Aug 23, 2020
A differential response in bioavailability was observed with ∼100 nm or smaller particles resulting in higher average exposure compared to ∼200 nm or larger particles. This increase in bioavailability could not be fully accounted for by the improvement in dissolution rate and was not as pronounced as that achieved by improving solubilization by co-administration with a high fat meal.
- || anacetrapib (MK-0859) / Merck (MSD)
Clinical, Journal: Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case. (Pubmed Central) - Jul 7, 2020
These data indicate that despite deposition and long-term residence of ~0.6 mmol/L levels of anacetrapib in adipose tissue, adipose tissue function appears to be unaffected in mice. In addition, these data also indicate that even with severe caloric restriction and acute loss of fat mass, anacetrapib does not appear to be mobilized from the fat depot, thereby solidifying the role of adipose as a long-term storage site of anacetrapib.
- | anacetrapib (MK-0859) / Merck (MSD)
Journal: Steering the lipid transfer to unravel the mechanism of CETP inhibition. (Pubmed Central) - Jun 26, 2020
Recently reported inhibitors, torcetrapib and anacetrapib, exhibited low potency in addition to severe side effects, which essentially demanded a thorough knowledge of the inhibition mechanism...Further, inhibitors bring about the conformational changes in CETP that hamper CE passage and expose protein residues that disrupt the optimal hydrophobicity of CE transfer path. The atomic level details presented here could accelerate the designing of safe and efficacious CETP inhibitors.
- | anacetrapib (MK-0859) / Merck (MSD)
Trial completion date: REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (clinicaltrials.gov) - Jun 17, 2020
P3, N=30449, Active, not recruiting, Sponsor: University of Oxford
The atomic level details presented here could accelerate the designing of safe and efficacious CETP inhibitors. Trial completion date: Apr 2019 --> Jan 2037
- | anacetrapib (MK-0859) / Merck (MSD)
Journal: Is Anacetrapib Better Than Its CETP Inhibitor Counterparts? (Pubmed Central) - Jan 19, 2020
This review will focus on high-density lipoprotein metabolism and transport, looking particularly at cholesteryl ester transfer protein (CETP) inhibitors. While studies of the other CETP inhibitors in its class have not shown a significant improvement in the prevention of primary or secondary cardiovascular risk, anacetrapib, the fourth and latest of the CETP inhibitors to be investigated, may be more promising.
- || anacetrapib (MK-0859) / Merck (MSD)
Finally an exclusive Rx for Lp(a). PCSK9i and Anacetrapib also reduce Lp(a).. Good for Indians (Twitter) - Jan 3, 2020
- | anacetrapib (MK-0859) / Merck (MSD)
Review, Journal: CETP inhibition, statins and diabetes. (Pubmed Central) - Nov 23, 2019
However, unlike statins, anacetrapib decreases the risk of developing diabetes. If the reduced risk of new-onset diabetes is confirmed in another CETP inhibitor outcome trial, there will be a case for considering the use of the combination of a statin plus a CETP inhibitor in high ASCVD-risk people who are also at increased risk of developing diabetes.
- | evacetrapib (LY2484595) / Eli Lilly, dalcetrapib (JTT-705) / Roche, Japan Tobacco, anacetrapib (MK-0859) / Merck (MSD)
Review, Journal: Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists. (Pubmed Central) - Nov 23, 2019
The pharmacological approach to the CETP system remains enigmatic, although the failure of CETP antagonists has dampened enthusiasm. Studies on the system, a crossroad for any investigation on cholesterol metabolism, have however provided crucial contributions and will still be confronting any scientist working on CV prevention.
- | evacetrapib (LY2484595) / Eli Lilly, dalcetrapib (JTT-705) / Roche, Japan Tobacco, anacetrapib (MK-0859) / Merck (MSD)
Review, Journal: Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week. (Pubmed Central) - Nov 23, 2019
In the 30,000-patient REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification) trial, anacetrapib doubled HDL cholesterol, reduced non-HDL cholesterol by 17 mg/dl (0.44 mmol/l), and reduced major vascular events by 9% over 4 years, but anaceptrapib was found to accumulate in adipose tissue, and regulatory approval is not being sought. Therefore, despite considerable initial promise, CETP inhibition provides insufficient cardiovascular benefit for routine use.
- | anacetrapib (MK-0859) / Merck (MSD)
Review, Journal: Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation. (Pubmed Central) - Nov 4, 2019
The CETP inhibitor anacetrapib reproduced the phenotype of homozygous CETP deficiency and showed a highly significant benefit for CAD in the REVEAL trial...In addition, clonal hematopoiesis has emerged as an important CAD risk factor, likely involving macrophage inflammation and inflammasome activation. Further elucidation of the mechanisms linking plaque accumulation of cholesterol and oxidized lipids to myeloid cell inflammation may lead to the development of new therapeutics specifically targeting atherogenic inflammation, with likely benefit for CAD.
- | anacetrapib (MK-0859) / Merck (MSD)
Clinical, PK/PD data, Journal: Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects. (Pubmed Central) - Nov 2, 2019
Anacetrapib was generally well tolerated in this study. The results of this study suggest that there may be race-related differences in pharmacodynamics of anacetrapib independent of pharmacokinetics.
- anacetrapib (MK-0859) / Merck (MSD)
The Effects of Anacetrapib on Occlusive Vascular Events During Post-Trial Follow-Up of the REVEAL Randomized Trial (Moderated Posters 1, Science and Technology Hall) - Oct 17, 2019 - Abstract #AHA2019AHA_8755;
The present results indicate that there are further benefits after prolonged follow-up. No safety concerns emerged for non-vascular mortality or morbidity during the post-trial period.
- | evacetrapib (LY2484595) / Eli Lilly, dalcetrapib (JTT-705) / Roche, Japan Tobacco, anacetrapib (MK-0859) / Merck (MSD)
Clinical, Clinical data, Journal: What have we learnt from the clinical outcomes trials with the cetrapibs? (Pubmed Central) - Sep 28, 2019
No safety concerns emerged for non-vascular mortality or morbidity during the post-trial period. Collectively, these clinical outcome trials do not support raising HDL cholesterol by inhibiting cholesteryl ester transfer protein, as a mechanism for improving cardiovascular outcomes, in the total population of subjects with coronary artery disease.
- anacetrapib (MK-0859) / Merck (MSD)
Impact of Haptoglobin Genotype and Diabetes Status on Anacetrapib-Mediated Increase in Cholesterol Efflux Capacity (Zone 1, Science and Technology Hall) - Sep 20, 2019 - Abstract #AHA2019AHA_8163;
Among diabetic patients with CHD, the effect of ANA on raising CEC was blunted in those with a Hp CNV linked to dysfunctional HDL. These findings warrant validation and suggest a strategy to identify those most likely to benefit from interventions targeting reverse cholesterol transport.
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Simdax (levosimendan IV) / AbbVie
Clinical, Review, Journal: Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials. (Pubmed Central) - Sep 1, 2019
These findings warrant validation and suggest a strategy to identify those most likely to benefit from interventions targeting reverse cholesterol transport. This paper presents a summary of key clinical cardiology trials during the past year and should be of practical value to both clinicians and cardiology researchers.
- | anacetrapib (MK-0859) / Merck (MSD)
Preclinical, Journal: Characterization of anacetrapib distribution into the lipid droplet of adipose tissue in mice and human cultured adipocytes. (Pubmed Central) - Aug 30, 2019
In vivo, the entry of anacetrapib into adipose tissue did not require lipase activity, as the distribution of anacetrapib into adipose was not affected by systemic lipase inhibition using oloaxamer-407, a systemic lipase inhibitor. The data from these studies support the notion that entry of anacetrapib into adipose tissue/lipid droplet does not require active transport or by mobilization and entry of fat into adipose via lipolysis.
- | anacetrapib (MK-0859) / Merck (MSD), Repatha (evolocumab) / Amgen, Astellas, Ilaris (canakinumab) / Novartis
Journal: An update on trials of novel lipid-lowering drugs. (Pubmed Central) - Aug 9, 2019
The data from these studies support the notion that entry of anacetrapib into adipose tissue/lipid droplet does not require active transport or by mobilization and entry of fat into adipose via lipolysis. Despite the success of proprotein convertase subtilisin kexin-9 inhibition, the ability to achieve low LDL-C with off-patent medications and the costs of novel therapies will limit their use even in high-risk patients and confine them to the highest-risk sub-groups of patients.
- | anacetrapib (MK-0859) / Merck (MSD)
Journal: Impact of ADCY9 Genotype on Response to Anacetrapib. (Pubmed Central) - Jul 25, 2019
P3
It provides no support for the hypothesis that ADCY9 genotype is materially relevant to the clinical effects of the CETP inhibitor anacetrapib. The ongoing dal-GenE study will provide direct evidence as to whether there is any specific pharmacogenetic interaction with dalcetrapib.
- | anacetrapib (MK-0859) / Merck (MSD)
Clinical, Journal: Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study. (Pubmed Central) - Jul 24, 2019
In this population-based study, there was no causal relation between genetically determined CETP concentration and cIMT in the total population although we observed directionally differing effects in men and women. Stratified results suggested associations in individuals with different cardiometabolic risk factor profiles, which require replication.
- | evacetrapib (LY2484595) / Eli Lilly, dalcetrapib (JTT-705) / Roche, Japan Tobacco, anacetrapib (MK-0859) / Merck (MSD)
Journal: The Trials and Tribulations of CETP Inhibitors. (Pubmed Central) - Jun 22, 2019
Anacetrapib treatment was associated with a small increase in BP, but was devoid of major side effects and was also associated with a small reduction in diabetes. Treatment with CETP inhibitors, either alone or in combination with statins, could provide another option for patients with coronary disease who require further reduction in LDL and/or non-HDL cholesterol.
- | DS-9001 / Daiichi Sankyo
Journal: Generation and Characterization of a Novel Small Biologic Alternative to PCSK9 Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein. (Pubmed Central) - May 24, 2019
Since bacterial production systems are viewed as more suited to mass production at low cost, DS-9001a may provide a new therapeutic option to treat a large number of patients with dyslipidemia. In addition, considering the growing demand for antibody-like drugs, ABD-fused Anticalin proteins could represent a promising new class of small biological molecules.
- | anacetrapib (MK-0859) / Merck (MSD)
Biomarker, Journal: Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile. (Pubmed Central) - May 22, 2019
Our results show that CETP is an important causal determinant of HDL and VLDL concentration and composition, which may imply that the CETP inhibitor anacetrapib decreased cardiovascular disease risk through specific reduction of small VLDL rather than LDL. The contrast between genetic and observational associations might be explained by a high capacity of VLDL, IDL and LDL subclasses to carry CETP, thereby concealing causal effects on HDL.
- || anacetrapib (MK-0859) / Merck (MSD)
Treatment effect of anacetrapib does not vary by <i>ADCY9</i><i> </i>genotype - #ACC19 #CHD #CardioTwitter @Oxford_NDPH https://t.co/p6DAIbg3Ou (Twitter) - Apr 3, 2019
- | anacetrapib (MK-0859) / Merck (MSD)
Trial completion, Trial completion date, Trial primary completion date: REVEAL-Vasc: The Effect of Anacetrapib on Vascular Function and Arterial Stiffness (clinicaltrials.gov) - Aug 16, 2018
P=N/A, N=103, Completed, Sponsor: Cambridge University Hospitals NHS Foundation Trust
The contrast between genetic and observational associations might be explained by a high capacity of VLDL, IDL and LDL subclasses to carry CETP, thereby concealing causal effects on HDL. Recruiting --> Completed | Trial completion date: Sep 2018 --> May 2018 | Trial primary completion date: Sep 2018 --> May 2018
- ||||||| anacetrapib (MK-0859) / Merck (MSD)
Trial completion: DEFINE: Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) (clinicaltrials.gov) - Dec 11, 2017
P3, N=1623, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | Trial completion date: Sep 2018 --> May 2018 | Trial primary completion date: Sep 2018 --> May 2018 Active, not recruiting --> Completed
- | anacetrapib (MK-0859) / Merck (MSD)
Journal: Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. (Pubmed Central) - Oct 7, 2017
P3
Conclusions Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .).
- | anacetrapib (MK-0859) / Merck (MSD)
Journal: A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. (Pubmed Central) - Sep 8, 2017
There were no clinically meaningful differences between the anacetrapib and placebo groups in the % patients who discontinued drug due to an adverse event or in abnormalities in liver enzymes, creatine kinase, blood pressure, electrolytes, or adjudicated cardiovascular events. Treatment with anacetrapib substantially reduced LDL-C and also increased HDL-C and was well tolerated over 24 weeks in statin-treated patients with hypercholesterolemia or low HDL-C.
- | anacetrapib (MK-0859) / Merck (MSD)
Enrollment change: REVEAL-Vasc: The Effect of Anacetrapib on Vascular Function and Arterial Stiffness (clinicaltrials.gov) - Jun 26, 2017
P=N/A, N=130, Recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
Treatment with anacetrapib substantially reduced LDL-C and also increased HDL-C and was well tolerated over 24 weeks in statin-treated patients with hypercholesterolemia or low HDL-C. N=90 --> 130
- | anacetrapib (MK-0859) / Merck (MSD)
Journal: Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. (Pubmed Central) - May 27, 2017
There were no meaningful differences between the anacetrapib 25 mg, 100 mg, and placebo groups in the proportions of discontinuations due to drug-related adverse events (0.7%, 1.3% vs 1.3%) or in abnormalities in liver enzymes (0%, 0% vs 0.7%), creatine kinase elevations overall (0%, 0.7% vs 0%) or with muscle symptoms (none seen), blood pressure, electrolytes, or adjudicated cardiovascular events (0.7%, 0.7% vs 1.3%). In conclusion, treatment with anacetrapib resulted in substantial reductions in LDL-C and increases in HDL-C and was generally well tolerated.
- anacetrapib (MK-0859) / Merck (MSD)
Enrollment open, Trial initiation date: REVEAL-Vasc: The Effect of Anacetrapib on Vascular Function and Arterial Stiffness (clinicaltrials.gov) - Jan 11, 2017
P=N/A, N=90, Recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
In conclusion, treatment with anacetrapib resulted in substantial reductions in LDL-C and increases in HDL-C and was generally well tolerated. Not yet recruiting --> Recruiting | Initiation date: Oct 2016 --> Jan 2017
- anacetrapib (MK-0859) / Merck (MSD)
New trial: REVEAL-Vasc: The Effect of Anacetrapib on Vascular Function and Arterial Stiffness (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=90, Not yet recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
- ||||||| anacetrapib (MK-0859) / Merck (MSD)
Trial completion: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022) (clinicaltrials.gov) - Aug 27, 2015
P3, N=589, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting | Initiation date: Oct 2016 --> Jan 2017 Active, not recruiting --> Completed
- ||||| anacetrapib (MK-0859) / Merck (MSD)
Enrollment change: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022) (clinicaltrials.gov) - Jun 25, 2015
P3, N=589, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=800 --> 589
- ||||| anacetrapib (MK-0859) / Merck (MSD)
Enrollment closed: REALIZE: Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) (clinicaltrials.gov) - Apr 8, 2015
P3, N=306, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=800 --> 589 Completed --> Active, not recruiting
- ||||||| anacetrapib (MK-0859) / Merck (MSD)
Trial completion: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1) (clinicaltrials.gov) - Mar 12, 2015
P3, N=307, Completed, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Active, not recruiting Active, not recruiting --> Completed
- ||||| anacetrapib (MK-0859) / Merck (MSD)
Enrollment closed: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022) (clinicaltrials.gov) - Dec 6, 2014
P3, N=800, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| anacetrapib (MK-0859) / Merck (MSD)
Trial completion: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021) (clinicaltrials.gov) - Nov 25, 2014
P3, N=459, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- anacetrapib (MK-0859) / Merck (MSD)
Trial termination: Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) (clinicaltrials.gov) - Jun 27, 2014
P3, N=2, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- anacetrapib (MK-0859) / Merck (MSD)
Enrollment change, Trial termination: Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) (clinicaltrials.gov) - Jun 27, 2014
P3, N=2, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Terminated N=45 --> 2 | Active, not recruiting --> Terminated
- ||||||| anacetrapib (MK-0859) / Merck (MSD)
Trial completion: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050) (clinicaltrials.gov) - May 26, 2014
P3, N=68, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=45 --> 2 | Active, not recruiting --> Terminated Active, not recruiting --> Completed
- |||| anacetrapib (MK-0859) / Merck (MSD)
Trial completion: A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029) (clinicaltrials.gov) - May 26, 2014
P2b, N=408, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| anacetrapib (MK-0859) / Merck (MSD)
Enrollment closed: REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (clinicaltrials.gov) - Apr 15, 2014
P3, N=30624, Active, not recruiting, Sponsor: University of Oxford
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- anacetrapib (MK-0859) / Merck (MSD)
Enrollment closed: A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029) (clinicaltrials.gov) - Mar 20, 2014
P2b, N=408, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- ||||||| anacetrapib (MK-0859) / Merck (MSD)
Trial completion: REALIZE: Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) (clinicaltrials.gov) - Mar 10, 2014
P3, N=306, Completed, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Active, not recruiting Active, not recruiting --> Completed
- | anacetrapib (MK-0859) / Merck (MSD)
Enrollment closed: Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) (clinicaltrials.gov) - Feb 16, 2014
P3, N=45, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | anacetrapib (MK-0859) / Merck (MSD)
Enrollment closed: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021) (clinicaltrials.gov) - Feb 12, 2014
P3, N=450, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| anacetrapib (MK-0859) / Merck (MSD)
Enrollment closed: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1) (clinicaltrials.gov) - Dec 10, 2013
P3, N=300, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting